Department of Anesthesia, Hospital of the University of Pennsylvania, Philadelphia, USA.
Department of Anesthesia, PGIMER, Chandigarh, India.
Ann Thorac Med. 2014 Jan;9(1):23-8. doi: 10.4103/1817-1737.124437.
Anesthesia for bronchoscopy presents unique challenges, as constant stimulus due to bronchoscope needs to be obtunded using drugs with a minimal post-procedure residual effect. Remifentanil for maintenance is an ideal choice, but optimal doses are yet to be determined.
Bronchoscopic procedures were prospectively evaluated for 4 months studying the frequency of complications and anesthesia techniques. Anesthesia was maintained on remifentanil/propofol infusion avoiding neuromuscular blockers. Laryngeal mask airway was used for the controlled ventilation (with high oxygen concentration) that also served as a conduit for bronchoscope insertions. Anesthesiologists were blinded to the study (avoiding performance bias) and the Pulmonologist was blinded to the anesthesia technique (to document unbiased procedural satisfaction scores). Procedures were divided into 2 groups based on the dose of remifentanil used for maintenance: Group-H (high dose -0.26 to 0.5 μg/kg/min and Group-NH (non-high dose ≤0.25 μg/kg/min).
Observed 75 procedures were divided into Group-H (42) and Group-NH (33). Number of statistical difference was found in demography, procedural profile, hemodynamic parameters and total phenylephrine used. Chi-square test showed Group-NH had significantly higher frequency of laryngospasm (P = 0.047) and coughing (P = 0.002). The likelihood ratio of patient coughing and developing laryngospasm in Group-NH was found to be 4.56 and 10.97 times respectively. Minimum pulse-oximeter saturation was statistically higher in Group-H (98.80% vs. 96.50% P = 0.009). Pulmonologist satisfaction scores were significantly better in Group-H.
High dose of remifentanil infusion is associated with a lower incidence of coughing and laryngospasms during bronchoscopy. Simultaneously, it improves Pulmonologist's satisfaction and procedural conditions.
支气管镜检查的麻醉具有独特的挑战,因为需要使用药物来减轻支气管镜不断刺激的影响,同时药物的术后残留作用要最小化。瑞芬太尼维持麻醉是理想的选择,但最佳剂量仍有待确定。
前瞻性评估了 4 个月的支气管镜检查过程中的并发症和麻醉技术的频率。使用瑞芬太尼/丙泊酚输注维持麻醉,避免使用神经肌肉阻滞剂。喉罩气道用于控制通气(高浓度氧气),也作为支气管镜插入的通道。麻醉师对研究不知情(避免操作偏见),而 Pulmonologist 对麻醉技术不知情(记录无偏见的程序满意度评分)。根据维持麻醉使用的瑞芬太尼剂量,将手术分为 2 组:高剂量组(0.26 至 0.5 μg/kg/min)和非高剂量组(≤0.25 μg/kg/min)。
观察到 75 例手术,分为高剂量组(42 例)和非高剂量组(33 例)。在人口统计学、手术过程、血液动力学参数和总苯肾上腺素使用方面发现了统计学差异。卡方检验显示,非高剂量组的喉痉挛(P = 0.047)和咳嗽(P = 0.002)频率明显更高。非高剂量组患者咳嗽和发生喉痉挛的可能性比在高剂量组分别为 4.56 倍和 10.97 倍。高剂量组的最低脉搏血氧饱和度统计学上更高(98.80% vs. 96.50%,P = 0.009)。高剂量组的 Pulmonologist 满意度评分明显更好。
瑞芬太尼输注高剂量与支气管镜检查期间咳嗽和喉痉挛的发生率降低相关。同时,它提高了 Pulmonologist 的满意度和手术条件。